Phase 3 randomized clinical trials of simufilam in mild-to-moderate Alzheimer’s disease
Simufilam did not meet co-primary or secondary endpoints in these Phase 3 trials. Simufilam was safe and well tolerated. Trials registered at clinicaltrials.gov: NCT04994483 and NCT05026177.
Authors
- Suzanne Hendrix (ORCID: https://orcid.org/0000-0002-2374-7727)
- Lindsay H. Burns (ORCID: https://orcid.org/0000-0002-4303-3174)
- Craig Mallinckrodt
- Roger Clarnette
- Raymond Scott Turner (ORCID: https://orcid.org/0000-0001-7534-2935)
- James W. Kupiec
- Arifulla Khan
- Kee Hyung Park
- Anton P. Porsteinsson
- Antonio M. Hernandez
- Ian Cohen
- Jonathan Liss
Institutions
- Gachon University (KR)
- York University (CA)
- Brain Research Foundation (US)
- Cassava Sciences (United States) (US)
- Gachon University Gil Medical Center (KR)
- Northwest Clinical Research Center (US)
- Cambridge Cognition (United Kingdom) (GB)
- TetraLogic Pharmaceuticals (United States) (US)
- Dementia Australia (AU)
- University of Rochester (US)
Publication Details
- Journal
- The Journal of Prevention of Alzheimer s Disease
- Published
- 2026-01-06
- DOI
- https://doi.org/10.1016/j.tjpad.2025.100469
- Citations
- 1
- Primary Topic
- Phosphodiesterase function and regulation
- Type
- article
- Field-Weighted Citation Impact
- 22.24